What is the recommended antimicrobial therapy for Klebsiella aerogenes infections in hospitalized or immunocompromised adults?

Antimicrobial Therapy for Klebsiella aerogenes Infections

For hospitalized or immunocompromised adults with Klebsiella aerogenes infections, carbapenems (meropenem, imipenem-cilastatin, or doripenem) are the preferred first-line agents, with treatment selection guided by antimicrobial susceptibility testing and local resistance patterns.

Understanding K. aerogenes Resistance Mechanisms

K. aerogenes (formerly Enterobacter aerogenes) belongs to the Enterobacter species group that possesses a chromosomal AmpC β-lactamase that is inducible and easily expressed at high levels through mutation 1. This results in:

• Intrinsic resistance to oxyimino-β-lactams (third-generation cephalosporins like ceftriaxone, ceftazidime)
• Intrinsic resistance to β-methoxy-β-lactams (cefoxitin, cefotetan)
• Maintained susceptibility to carbapenems (unless additional resistance mechanisms develop)

The organism can also acquire plasmid-mediated resistance including ESBL production, which is increasingly recognized in Enterobacter species 1. Recent genomic analyses confirm K. aerogenes carries multiple resistance genes and can harbor carbapenemases (KPC, NDM, IMP, VIM) and ESBL genes, though these are less common than in K. pneumoniae 2.

Treatment Algorithm

Step 1: Initial Empiric Therapy Selection

For healthcare-associated infections or high-severity community-acquired infections:

• Preferred regimens 3:
  • Meropenem 1-2g IV every 8 hours
  • Imipenem-cilastatin 500mg IV every 6 hours or 1g every 8 hours
  • Doripenem 500mg IV every 8 hours
  • Piperacillin-tazobactam 4.5g IV every 6 hours (if local susceptibility data support use)

Avoid these agents for empiric therapy:

• Third-generation cephalosporins (ceftriaxone, ceftazidime) - high risk of treatment failure due to AmpC induction 1
• Ampicillin-sulbactam - high resistance rates 3
• Fluoroquinolones as monotherapy - unless local susceptibility >90% 3

Step 2: Tailor Therapy Based on Susceptibility Results

Once culture and susceptibility data are available 3:

If carbapenem-susceptible:

• Continue carbapenem monotherapy
• De-escalate to narrower spectrum agents if susceptible (e.g., piperacillin-tazobactam)

If ESBL-producing but carbapenem-susceptible:

• Carbapenems remain the treatment of choice 4, 1
• ESBL-producing strains maintain carbapenem susceptibility 1

If carbapenem-resistant (rare but emerging):

• Ceftazidime-avibactam (covers KPC, some OXA-48) 5, 6
• Meropenem-vaborbactam (covers KPC) 6, 7
• Polymyxins (colistin/polymyxin B) in combination therapy 6
• Tigecycline (avoid in bacteremia due to poor serum concentrations) 5
• Cefiderocol (covers MBL-producers) 8

Step 3: Special Considerations by Infection Site

Urinary tract infections:

• Carbapenems preferred 9
• Aminoglycosides (gentamicin, amikacin) are alternatives if susceptible, particularly for cystitis 8, 10
• Avoid tigecycline (poor urinary concentrations) 8

Bloodstream infections:

• Carbapenems as monotherapy 7
• Avoid tigecycline monotherapy (associated with higher mortality in bacteremia) 5, 6
• For carbapenem-resistant isolates, combination therapy with polymyxins plus carbapenem or tigecycline 6

Intra-abdominal infections:

• Carbapenems provide both Enterobacter coverage and necessary anaerobic coverage 3
• Combination with metronidazole unnecessary (carbapenems cover anaerobes)

Pneumonia (HAP/VAP):

• Carbapenems or piperacillin-tazobactam 4
• Avoid aminoglycoside monotherapy 4

Critical Pitfalls to Avoid

1. Never use third-generation cephalosporins (ceftriaxone, cefotaxime) even if in vitro susceptible - high risk of treatment failure due to AmpC induction during therapy 1

2. Fourth-generation cephalosporins (cefepime) are controversial - while theoretically more stable against AmpC, clinical data for Enterobacter species are limited and resistance can still develop 1

3. Do not rely on empiric fluoroquinolones unless local E. coli susceptibility is >90%, as this predicts Enterobacter susceptibility 3

4. Combination therapy is not routinely needed for carbapenem-susceptible isolates in non-bacteremic patients 4

5. For immunocompromised patients, consider empiric enterococcal coverage (add ampicillin or vancomycin) until cultures finalize 3

Duration and Monitoring

• Source control is essential - drainage of abscesses, removal of infected devices 3
• Typical duration: 7-14 days depending on infection site and clinical response
• Obtain repeat cultures if clinical response is inadequate after 48-72 hours
• Monitor for secondary resistance development during prolonged therapy

Carbapenem-Sparing Strategies

In settings with high carbapenem-resistant Enterobacteriaceae prevalence, consider 5:

• Piperacillin-tazobactam for non-ESBL producers
• Ceftolozane-tazobactam plus metronidazole (for intra-abdominal infections)
• However, carbapenems remain preferred for serious infections in hospitalized/immunocompromised patients 1, 3

The key principle is that K. aerogenes requires broader-spectrum therapy than typical community-acquired Enterobacteriaceae due to its chromosomal AmpC β-lactamase, making carbapenems the most reliable empiric choice pending susceptibility data 1.